Views & Analysis Addressing MS’ two-tier healthcare system is about ‘social j... NICE has reversed its decision not to approve a new drug that offers hope to thousands o
News Roche’s MS drug Ocrevus earns blockbuster status a year afte... Roche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster status just one year after it was launched.
News Roche’s MS drug Ocrevus nears European market Roche's new multiple sclerosis drug Ocrevus (ocrelizumab) gained FDA approval in March, and since then has achieved remarkable revenues of half a billion dollars in the year to date.<
News Brain infection would be bad news for Roche's MS drug Ocrevu... Suggestion is that PML case was caused by previous treatment.
Oncology On looking to a future multiomics approach for CDx, with Jan... The pharmaphorum podcast caught up with Jane Li, VP and general manager for companion diagnostics at Thermo Fisher Scientific, following ESMO 2026.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.